A revolutionary cancer treatment could transform autoimmune disease

A revolutionary cancer treatment could transform autoimmune disease therapy, redefining how we treat lupus or rheumatoid arthritis by targeting root causes rather than symptoms. CAR-T cell therapy, originally designed for blood cancers, has shown a 75% remission rate in lupus patients in early trials. By genetically reprogramming a patient's T cells to attack faulty B cells, the therapy achieves durable remissions—a stark contrast to the typical 50% response rate of standard biologics. The data, published in Nature Medicine, signals a shift toward precision immunotherapy for autoimmune conditions.